Abstract tion analysis; renal transplantation; steroid withdrawal; T helper lymphocytes Background. Even in low doses, long-term steroid immunosuppression is known to cause serious complications. However, the safety of steroid withdrawal has not been proven in randomized clinical trials. This
( HTLpf ), with the clinical outcome of 21 consecutive alternate days. During PRED taper and 2 months thereafter, renal transplanted patients on standard triple therapy. patients were observed closely on regular bases, and serum
We found that in a proportion of patients, the developcreatinine level was monitored at least once a week. The ment of donor-specific hyporeactivity was associated taper was halted or aborted if rejection was suspected on the with better graft outcome as evidenced by fewer late basis of standard clinical criteria or if serum creatinine level rejection episodes, stable renal graft function and suc-rose by more than 15% in two consecutive measurements in cessful steroid withdrawal for at least 6 months. This the absence of other causes of deterioration of renal function, indicates that the development of in vitro donor specific such as CsA nephrotoxicity or infection. If rejection was hyporeactivity as detected by LDA of HTLpf may be confirmed by biopsy, then the PRED was reinstated in a total daily dose of 20 mg, thereafter gradually tapered to a used as an additional tool along with the available maintenance dose of daily 5 mg and no future attempt was clinical criteria for identifying those patients in whom made to withdraw the steroids. steroid withdrawal would be safe.
According to the clinical outcome patients were divided to two groups. First group, steroid withdrawn (SW ) group: those patients in whom steroid withdrawal was successful
Subjects and methods
for at least 6 months; second group, steroid continued (SC ) group: those patients in whom steroid withdrawal has failed Patients because of rejection or significant rise in serum creatinine level after attempting steroid tapering, or in whom steroid Between November 1993 and November 1994, 21 consecutive withdrawal was not attempted. patients (11 males and 10 females) aged between 23 and 68 years who received cadaveric renal allografts for end-stage Rejection diagnosis renal failure were studied. The study was carried out in accordance with the guidelines of the local ethical committee Diagnosis of rejection was made based on standard clinical and written informed consent was obtained in all cases.
criteria and confirmed by biopsy in most cases. Histological assessment of biopsies was carried out and reported by three HLA typing independent histopathologists. Episodes of acute rejection were treated by steroid pulses and OKT3 in resistant episodes. The mean number of HLA mismatches between donor and recipients is shown in Table 1 , and was carried out as Blood samples described previously [12 ] .
Heparinized blood was collected from patients before transplantation ( T0 ) and at appropriate diÂerent time points after Immunosuppression transplantation. Blood samples were also taken from laboratory or hospital worker healthy volunteers at appropriate The immunosuppression therapy was based on cyclosporin (CsA), azathioprine ( AZA), and prednisolone (PRED) in time points. Peripheral blood mononuclear cells (PBMC ) were isolated from patients or healthy volunteers by standard all these recipients. The initial dose of CsA was 5 mg/kg twice a day, adjusted according to whole blood trough density gradient centrifugation ( Lymphoprep; Nycomed, Norway). level using standard radioimmunoassay ( blood level 100-200 mg/l ). The patients received AZA in a constant dose of 1.5 mg/kg/day as long as the white cell count did not fall Donor spleen cells bellow 4×109/l. The initial dose of PRED was 10 mg twice a day in the first 3 months, which was gradually reduced by Donor splenic mononuclear cells (DSMC) were isolated as 5 mg every 3 months, so that by the end of the year the described above after gentle disaggregation of donor splenic patient received 5 mg or 0.
tissues in cold RPMI 1640 medium. DSMC were stored in Steroid withdrawal was attempted in patients who never 1-ml aliquots in liquid nitrogen until used. experienced rejection episodes or in three cases who had only one very mild rejection episode (BanÂ classification [13 ] : borderline changes): and additionally had stable renal func-Flow cytometry tion (defined as stable serum creatinine level below 200 mmol/l for at least 6 months after transplantation). All patients who The number of CD3+ cells in each patient or volunteer PMNC sample added per experiment was determined using were selected for steroid withdrawal were maintained on triple therapy (CsA, AZA, PRED) prior to steroid with-flow cytometry by immunofluorescence staining. Each sample was divided into two, one incubated with 10 ml PE-labelled drawal and subsequently were maintained on CsA and AZA. PRED was tapered gradually (over 3-4 months) followed by anti-CD3 ( Becton Dickinson, CA, USA) for 45 min at 4°C Results are expressed as mean±SD number of mismatches.
Steroid withdrawal and hyporeactivity after transplantation on triple therapy 1951 and the other with isotype-matched control antibodies hospital or laboratory staÂ at diÂerent appropriate time points. We repeatedly found that Con A stimulated mitomy-( Becton Dickinson). After two washes in cold PBS, cells were fixed with 1% paraformaldhyde and stored in the dark cin C inactivated stimulator mononuclear cells did not produce IL-2. The chosen mitomycin C dose did not greatly at 4°C until analysis. Immunofluorescence was measured on Epics Profile-II Coulter Counter flow cytometer. Markers reduce allostimulatory capability of the stimulator cells (unpublished results). As a control, CTLL-2 cells were also were set based on background staining with the isotypematched control antibodies. Data were stored into list-mode incubated with increasing concentrations of rIL-2. The culture period of 72 h was found to be optimal for measuring files until further analysed using Flowmate software ( Dako Ltd, UK ).
the IL-2 production by a single cell type and the assays conformed to single-hit kinetics, indicating that IL-2 production was dependent on a single limiting cell type. In general
Culture medium
the HTLpf of the healthy volunteers were found to be similar with overlapping 95% CI and<twofold variation during the The culture medium was RPMI 1640 (Gibco; Paisley, UK ) monitoring period (results not shown). supplemented with 10% heat inactivated fetal calf serum (Sigma; Dorset, UK ), 25 mM of hepes buÂer, 2 mM L-glutamine, 100 mg/ml penicillin and streptomycin and Results 5×10-5 M 2-mercaptoethanol (Sigma) and was used throughout the study.
Steroid withdrawal Limiting dilution analysis of HTLpf
Of the total 21 patients studied, PRED was withdrawn completely in nine patients for average of 380±165 The LDA is based on a bioassay for IL-2 detection using days (range 187-684) and PRED was continued in 12 the IL-2 dependent CTLL-2 as described previously in detail patients. Among the 9/21 patients in whom PRED was [ 14, 15] . Briefly, serial dilutions of responder PMNC were withdrawn, PRED was reinstated in two patients at cultured in 96-well microtitre plate (Nunc, Denmark) in 24 210 and 187 days respectively after PRED withdrawal.
replicates together with 20 000 appropriate mitomycin C
The reasons for restarting PRED in these two patients inactivated stimulator mononuclear cells, either donor spleenwere mild acute rejection episode confirmed by biopsy derived or third party (a mixture of spleen cells from 10 in one patient; the other patient had a significant rise donors) in a total volume of 200 ml. After 72 h of incubation, 100 ml of supernatant was transferred from each well to 96 in serum creatinine level but no acute rejection episode flat-bottom microtitre plate (Nunc) for detection of IL-2 was confirmed. In this patient the PRED was restarted using the IL-2 dependant CTLL-2 cells. Proliferation of at a total dose of 2.5 mg/day. In both these patients CTLL-2 was assessed by [3H ]-thymidine incorporation over the serum creatinine level returned to the level before 8 h. Individual microcultures were considered positive for withdrawal in 4 weeks time after restarting the PRED.
IL-2 secretion in wells that exhibited proliferation greater PRED was not withdrawn in 12/21 patients because than the mean plus 3 times the SD of 24 control wells of previous significant acute rejection episode in eight containing supernatant of stimulator cells only.
patients or unsuccessful complete withdrawal of PRED in four patients because of significant rise of serum Statistical analysis creatinine level after PRED tapering to below 5 mg/day. PRED requirement was not correlated with The HTLpf in each assay was calculated based on the HLA-compatibility (Table 1 ) .
Poisson distribution method, and was corrected for number of CD3+ cells. The number of the frequency, 95% confidence intervals (CI ), and the probability for single-hit kinetics were Rejection episodes estimated by maximum likelihood analysis using the A total of four rejection episodes occurred in four of Jackknife modification of the x2 minimization as described nine patients in the SW group, three before steroid by Taswell [ 16 ] using computer software [17 ] . Assays were considered to conform to single-hit kinetics when the good-withdrawal (see material and method ) and one at 207 ness of fit was<12.5 and P value>0.05 as calculated by x2 days after PRED withdrawal. In the SC group a total analysis. Assays for which P value was<0.05 were excluded. of 16 rejection episodes occurred in nine of 12 patients, Individual HTLpf were considered to be statistically diÂerent 12 within 6 months and four episodes after 6 months when the 95% CI did not overlap. As appropriate, post-tx. No grafts were lost from chronic rejection in Mann-Whitney U test, Fisher's exact test, and paired or the SW or SC group after a mean follow up of unpaired Student t test were used to compare between the 854±102 days ( range 714-1083).
groups. Statistical significance was defined as P value <0.05. A patient was considered as hyporesponsive to his donor antigen if the donor-reactive HTLpf reduced at least fivefold Renal function (as compared to pre-tx) at least two time points post-tx
In the nine patients in whom PRED was discontinued, provided that the post-tx third-party-reactive HTLpf has not reduced by more than twofold. the mean serum creatinine was 138±24 before and 132±40 after PRED withdrawal (P=0.45). The mean serum creatinine at 18 months was significantly lower Reproducibility of the assays in the SW group than in the SC group, 132±40 and 173±39 respectively, (P=0.04). Table 2 summarizes Sensitivity and reproducibility of the assay was established by measuring HTLpf in diÂerent healthy volunteers from the results in both groups. Kinetics of HTLpf level. The mean (95% CI of mean) of the third-partyreactive HTLpf in these nine patients at diÂerent time The pre-tx values of donor-reactive HTLpf ranged points are as follows: at pre-tx 1/2760 (2044-3475 ), between 156-486 (/million) and were without a predict-before steroid withdrawal 1/3655 ( 2745-4563) and ive value for the clinical outcome. The post-tx values after steroid withdrawal 1/3586 (2395-4776). of donor-reactive HTLpf indicated that there were two
In 10 ( 10/12) patients in the SC group (Figure 2 ), diÂerent reactivities towards donors. In seven of nine both donor and third-party-reactive HTLpf remained patients in the SW group ( Figure 1) , the donor-reactive little changed (<threefold ) at 12 months post-tx as HTLpf determined at least 6 months after steroid compared to pre-tx. One of eight patients in whom no withdrawal were reduced at least fivefold (range 5-17) attempt was made to withdraw steroid showed a compared to pre-tx level, while third party-reactive significant decrease in post-tx donor-reactive HTLpf. HTLpf frequencies remained mostly unchanged
In four patients in this group in whom steroid with-(<twofold ) through the same period. In one (1/7) drawal was not successful, two had a high post-tx patient in whom complete steroid withdrawal was donor-reactive HTLpf in all the determinations. In the successful had a persistent high post-tx donor-reactive other two patients, one had an initial 1.5-fold reduction HTLpf. In two ( 2/9) patients in whom steroid within post-tx donor-reactive HTLpf but then increased drawal was not successful, one had a high post-tx during the last determination, the last patient showed donor-reactive HTLpf, and in the other patient the post-tx donor-reactive HTLpf decreased to a significant a significant decrease in post-tx donor-reactive HTLpf Fig. 1 . Significant reduction of post-transplant donor-reactive HTLpf in seven ( 7/9) cadaveric renal allograft recipients in whom steroid withdrawal succeeded for at least 6 months. All seven patients were free from the steroid until final evaluation (miniumum of 10 months after withdrawal ). In two patients steroid was reinstated after 6 months of withdrawal (see text). in all the determinations. The mean ( 95% CI of mean) [12] . In the present study we quantified the donorreactive HTLpf in a longitudinal study using LDA, of the third-party-reactive HTLpf in these 12 patients at diÂerent time points are as follow: at pre-tx 1/2394 known to be a powerful and sensitive technique [21] and we correlated these results with the success or ( 1951-2837), 6 months post-tx 1/3272 (2568-3975), and at 12 months post-tx 1/3519 (2627-4410).
failure of steroid withdrawal.
Our study provides evidence that the development of in vitro donor-specific hyporeactivity in certain Discussion patients as detected by LDA of HTLpf correlates with successful steroid withdrawal. In the SW group there were fewer rejection episodes ( 3 before and one after Several previous studies have reported the advantages steroid withdrawal ) compared with the SC group of steroid withdrawal after solid organ allotransplantwhere a total of 16 rejection episodes (12 within 6 ation. These advantages include lower incidence of months post-tx and four after 6 months) occurred in opportunistic infection [10] , lower incidence of catarnine patients. Whilst suggestive of better graft tolerance acts [9, 10] , lower serum lipids [3, 5, 10] , less hypertenthe diÂerences are not significant (P=0.06, Table 2 ). sion [3, 5, 9, 10 ] , good control of diabetes [10 ] , and In a study by Flechner et al.
[22 ] rejection episodes improved growth rate in young recipients [18 ] . These occurred in four of 21 recipients of HLA identical advantages should be weighed against the risk of grafts and in two of 12 recipients of haplo-identical chronic rejection and subsequent graft loss as a result grafts after steroid withdrawal. Flechner et al. selected of steroid withdrawal [1, 7] . Based on the standard candidates for steroid withdrawal based on low anticlinical criteria, the decision to withdraw steroid cannot donor reactivity as detected by MLR. A continuation be undertaken lightly, and it would be advantageous [9] of this study confirmed the excellent tolerance to if in vitro immunological assays could predict the safety steroid withdrawal in the donor-specific hyporesponsof steroid withdrawal.
ive patients after 5 years of follow-up. In another study Our focus has been on studying IL-2 production by Reinsmoen and Matas [23] , the development of in and proliferation, given the important role played by vitro donor specific hyporeactivity was found to be T helper lymphocytes in the initiation and the developassociated with a lower mean serum creatinine level at ment of organ allograft rejection [19, 20] , and the fact 6, 12, and 24 months following transplantation and that the majority of these T helper cells are proliferative fewer rejection episodes in 26% of renal allograft cells reactive with allogeneic MHC class II antigens.
recipients studied, as compared to patients who had Previously we quantified the alloreactive response by persistent reactivity towards donors 2 years postmeasuring the proliferation of T cells in MLR and we identified donor-specific hyporeactivity in 11/19 studied transplantation. However, no attempt was made to
